MERS-CoV: clinical diagnostic laboratory specimen handling and processing
- Public Health England
- Part of:
- Middle East respiratory syndrome coronavirus (MERS-CoV): clinical management and guidance
- First published:
- 18 April 2016
Interim guidance for staff in England, who handle samples from patients with suspected or laboratory-confirmed MERS-CoV infection.
Interim guidance: handling and processing of specimens associated with Middle East respiratory syndrome coronavirus (MERS-CoV) in clinical diagnostic laboratories
Ref: PHE publications gateway number: 2016031 PDF, 260KB, 8 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
Knowledge about the pathogenic potential and transmission risks for Middle East respiratory syndrome coronavirus (MERS-CoV) is incomplete and continues to evolve. This interim guidance is based on current knowledge and aims to minimise risks for laboratory staff handling specimens from patients with suspected or laboratory-confirmed MERS-CoV infection.
This guidance is specific to clinical diagnostic laboratory practice in England and may differ from guidance produced by agencies in other countries, including recommendations about biosafety levels.
Published: 18 April 2016